| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2203 | 2017 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1656 | 2018 |
| Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection JJ Feld, IM Jacobson, C Hézode, T Asselah, PJ Ruane, N Gruener, ... New England Journal of Medicine 373 (27), 2599-2607, 2015 | 1390 | 2015 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1211 | 2019 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1184 | 2016 |
| Early liver transplantation for severe alcoholic hepatitis P Mathurin, C Moreno, D Samuel, J Dumortier, J Salleron, F Durand, ... New England Journal of Medicine 365 (19), 1790-1800, 2011 | 1022 | 2011 |
| ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV P Ferenci, D Bernstein, J Lalezari, D Cohen, Y Luo, C Cooper, E Tam, ... New England Journal of Medicine 370 (21), 1983-1992, 2014 | 1012 | 2014 |
| Systemic inflammation in decompensated cirrhosis: characterization and role in acute‐on‐chronic liver failure J Clària, RE Stauber, MJ Coenraad, R Moreau, R Jalan, M Pavesi, ... Hepatology 64 (4), 1249-1264, 2016 | 789 | 2016 |
| EASL Clinical Practice Guidelines: Management of alcohol-related liver disease M Thursz, A Gual, C Lackner, P Mathurin, C Moreno, L Spahr, M Sterneck, ... Journal of hepatology 69 (1), 154-181, 2018 | 746 | 2018 |
| A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis S Buch, F Stickel, E Trépo, M Way, A Herrmann, HD Nischalke, M Brosch, ... Nature genetics 47 (12), 1443-1448, 2015 | 605 | 2015 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 575 | 2014 |
| A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH SM Francque, P Bedossa, V Ratziu, QM Anstee, E Bugianesi, AJ Sanyal, ... New England Journal of Medicine 385 (17), 1547-1558, 2021 | 505 | 2021 |
| The interleukin‐17 pathway is involved in human alcoholic liver disease A Lemmers, C Moreno, T Gustot, R Maréchal, D Degré, P Demetter, ... Hepatology 49 (2), 646-657, 2009 | 505 | 2009 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 471 | 2022 |
| Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment E Gane, E Lawitz, D Pugatch, G Papatheodoridis, N Bräu, A Brown, S Pol, ... New England Journal of Medicine 377 (15), 1448-1455, 2017 | 459 | 2017 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 420 | 2014 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 406 | 2020 |
| Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY‐3+) V Leroy, P Angus, JP Bronowicki, GJ Dore, C Hezode, S Pianko, S Pol, ... Hepatology 63 (5), 1430-1441, 2016 | 351 | 2016 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 337 | 2017 |
| Differential liver sensitization to toll‐like receptor pathways in mice with alcoholic fatty liver T Gustot, A Lemmers, C Moreno, N Nagy, E Quertinmont, C Nicaise, ... Hepatology 43 (5), 989-1000, 2006 | 295 | 2006 |
